TY - JOUR
T1 - Vaccine immunotherapy in breast cancer treatment
T2 - Promising, but still early
AU - Curigliano, Giuseppe
AU - Spitaleri, Gianluca
AU - Dettori, Manuela
AU - Locatelli, Marzia
AU - Scarano, Eloise
AU - Goldhirsch, Aron
PY - 2007/9
Y1 - 2007/9
N2 - Cancer vaccine-based immunotherapy should potentiate immunosurveillance function, preventing and protecting against growing tumors. Tumor cells usually activate the immune system, including T lymphocytes and natural killer cells, which are able to eliminate the transformed cells. Immunosubversion mechanisms related to tumor cells antigenic immunoediting induces mechanisms of tolerance and immunoescape. This condition impairs not only host-generated immunosurveillance, but also attempts to harness the immune response for therapeutic purposes. Most trials evaluating breast cancer vaccines have been carried out in patients in the metastatic and adjuvant setting. The aim of this review is to analyze the activity of vaccination strategies in current clinical trials. We summarize the differential approaches, protein-based and cell-based vaccines, focusing on vaccines targeting HER2/neu protein. Another focus of the review is to provide the reader with future challenges in the field, taking into account both the immunological and clinical aspects to better target the goal.
AB - Cancer vaccine-based immunotherapy should potentiate immunosurveillance function, preventing and protecting against growing tumors. Tumor cells usually activate the immune system, including T lymphocytes and natural killer cells, which are able to eliminate the transformed cells. Immunosubversion mechanisms related to tumor cells antigenic immunoediting induces mechanisms of tolerance and immunoescape. This condition impairs not only host-generated immunosurveillance, but also attempts to harness the immune response for therapeutic purposes. Most trials evaluating breast cancer vaccines have been carried out in patients in the metastatic and adjuvant setting. The aim of this review is to analyze the activity of vaccination strategies in current clinical trials. We summarize the differential approaches, protein-based and cell-based vaccines, focusing on vaccines targeting HER2/neu protein. Another focus of the review is to provide the reader with future challenges in the field, taking into account both the immunological and clinical aspects to better target the goal.
KW - Adjuvant therapy
KW - Breast cancer
KW - Metastatic therapy
KW - Peptide
KW - Vaccine
KW - Whole cell
UR - http://www.scopus.com/inward/record.url?scp=34948878051&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=34948878051&partnerID=8YFLogxK
U2 - 10.1586/14737140.7.9.1225
DO - 10.1586/14737140.7.9.1225
M3 - Article
C2 - 17892423
AN - SCOPUS:34948878051
VL - 7
SP - 1225
EP - 1241
JO - Expert Review of Molecular Diagnostics
JF - Expert Review of Molecular Diagnostics
SN - 1473-7159
IS - 9
ER -